CBD Oil for Dog Seizures: Study & Caution

Dog CBD Oil for Seizures: A New Study Shows Promise and a Key Caution

For dogs with epilepsy that doesn’t respond to standard medications, a new treatment option is showing potential. Researchers at Kasetsart University in Thailand have published a pilot study on using cannabidiol (CBD) for dogs with refractory epilepsy. The results offer hope for seizure reduction but highlight a critical need for veterinary monitoring.

Over 60% of Dogs Saw Major Seizure Reduction with CBD

Led by veterinarian K. Kimram, the Thai research team enrolled 13 dogs whose seizures were not controlled by two to six standard antiepileptic drugs (AEDs). These dogs experienced a median of 11 seizures in the observation period before starting CBD. The researchers added a CBD oil, titrating the dose from 0.5 mg/kg up to 2.5 mg/kg, given every 12 hours.

After the intervention, the median seizure frequency dropped to 5. This overall reduction was statistically significant. More compelling, 61.5% of the dogs—eight out of the thirteen—achieved a ≥50% reduction in how often they seized. The study also recorded a powerful effect on seizure clusters, which are particularly dangerous episodes of multiple seizures in a short time. The number of these clusters fell significantly, suggesting CBD may help stabilize brain activity over longer periods.

The mechanism behind this is thought to involve the body’s endocannabinoid system (ECS). The ECS helps regulate neurological activity, including excitability and inflammation. CBD is believed to interact with receptors in this system, potentially calming excessive electrical firing in the brain that leads to seizures, offering a complementary action to traditional AEDs.

A Clear Signal for Liver Monitoring Emerges from Blood Work

The study’s safety data presents a double-edged sword. Most hematological and kidney parameters in the dogs remained stable throughout the trial. However, the team found a consistent and significant increase in the liver enzyme Alkaline Phosphatase (ALP).

Elevated ALP can indicate stress on the liver, a common site for drug metabolism. Since all the study dogs were on multiple other AEDs, it is unclear if the rise was due to CBD alone, an interaction with other medications, or the combined load on the liver. This finding does not automatically mean CBD caused liver damage, but it acts as a clear flag. The authors stress that regular blood tests to monitor liver values are essential for any dog on long-term CBD, especially if they are taking other prescription drugs. This need for vigilance mirrors concerns in other areas of veterinary medicine, such as managing medications for end-stage canine heart disease, where balancing benefit and side-effect risk is constant.

Owners Report Better Life Quality, But Often Go It Alone

Quality of life, as reported by the dogs’ owners, improved alongside the seizure reduction. This subjective measure is vital, as managing chronic conditions like epilepsy focuses on wellbeing, not just symptom counts. The positive perception aligns with broader trends. A separate 2026 survey published in The Veterinary Journal by A. Besegher and colleagues examined CBD use among French pet owners.

That survey found that while many owners turn to CBD for conditions like anxiety, pain, and seizures, a majority do so without a direct recommendation from their veterinarian. This gap between owner adoption and formal veterinary guidance presents a challenge. It underscores the importance of studies like the one from Kasetsart University, which provide evidence and structured dosing frameworks to help veterinarians and owners make informed decisions together.

Implementing a “Start-Low, Go-Slow” Dosing Strategy

The Thai research provides a practical template for considering CBD. Their approach actively avoided a fixed, one-size-fits-all dose. Instead, they began with a low dose of 0.5 mg/kg twice daily and increased slowly based on the dog’s response and tolerance. This method aims to find the minimum effective dose for seizure control while minimizing potential side effects.

For pet owners, this means CBD should not be an over-the-counter experiment. It is a substance with measurable physiological effects, including on the liver. Starting a dog on CBD requires a veterinary diagnosis, especially for a complex condition like refractory epilepsy. It should be considered an adjunctive therapy, meaning it adds to—not replaces—existing AEDs unless a vet advises otherwise. Regular veterinary check-ups, including blood panels to monitor liver enzymes like ALP, become non-negotiable parts of the treatment plan. This personalized, monitored approach is similar to the precision needed in other modern treatments, such as the custom dosing possible with 3D-printed pimobendan for dogs.

Conclusion

The evidence indicates cannabidiol can be a valuable tool for managing drug-resistant canine epilepsy, with a majority of dogs experiencing substantially fewer seizures. However, its use demands a cautious, veterinary-supervised protocol due to its potential impact on liver metabolism and interactions with other drugs.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41463899/
https://pubmed.ncbi.nlm.nih.gov/41389569/
https://pubmed.ncbi.nlm.nih.gov/40968477/